

Follow us on Twitter and LinkedIn!



Dr Damien Dupin
Project Coordinator
CIDETEC
Email: ddupin@cidetec.es
Web: cidetec.es/en/home



Developing a Game-Changing
Treatment for Knee Osteoarthritis

www.osteoarthritis-sinpain.eu




> 500 million patients

Osteoarthritis (OA) ranks among the most common joint disorders worldwide




OA is a degenerative disease that can affect one or several joints, but most commonly the diarthrodial joints of the hip, hand and knee.

Major symptoms include:



SINPAIN strives to treat knee OA by developing an advanced, safe, efficient, and cost-effective nanotherapeutics pipeline based on siRNA.



So far, OA has no cure, and current treatment options are often ineffective, costly and invasive.




Locally administered therapeutic



The SINPAIN research will add to a deeper understanding of the complex disease mechanisms behind OA.



SINPAIN's innovative OA therapy is based on siRNA (small interfering ribonucleic acid), which seeks to deliver sequence-specific information to restore the healthy tissue environment.



SINPAIN aims to:

- Improve patients' quality of life, reduce pain and slow disease progression
- Reduce OA healthcare costs
- Understand the complex cellular crosstalk of OA
- Use curative RNA targeting specific cells
- Create prototypic therapies to modulate inflammation, innervation and regeneration
- Assess in vitro and in vivo safety of the prototypes
- Develop an artificial intelligence tool to aid in diagnosis

Specifically designed machine-learning tools will support the delivery of personalised therapies.

